Ketamine's clinical use began in the 1970s. Physicians benefited from its safety and ability to
induce short-term anesthesia and analgesia. The psychodysleptic effects caused by the …

Glutamate serves as the dominant central nervous system (CNS) excitatory neurotransmitter,
in part by activating N-methyl-D-aspartate receptors (NMDARs). While the structure, function …

Ketamine (Ket) was developed in 1962 as a less hallucinogenic and shorter acting agent
than phencyclidine. It was given to humans for the first time in 1964. However, Ket produces …

Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …

The Warburg effect or aerobic glycolysis is a hallmark of cancer. Lactate dehydrogenase
(LDH), which catalyzes conversion of pyruvate into lactate, serves a critical role during …

Breast cancer (BC) serves as a prevalent and mortal malignancy among female globally.
Ferroptosis, as an oxidative cell death that characterized by abnormal iron accumulation …

Ketamine is widely used for cancer pain treatment in clinic, and has been shown to inhibit
various tumor cells growth. However, the effect of ketamine on ovarian cancer cells growth …

Pancreatic ductal adenocarcinoma is one of the most aggressive solid tumours of the
pancreas, characterised by a five-year survival rate less than 8%. Recent reports that …

Propofol is a commonly used intravenous anesthetic, and could attenuate cancer cells
malignant potential via inhibiting hypoxia-inducible factor-1α (HIF-1α) expression. However …

Ketamine, a common N-methyl-d-aspartate receptor (NMDAR) antagonist, is an option for
cancer pain treatment in clinical practice. Ketamine has been shown to have the capacity to …